| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005986575 |
| P356 | DOI | 10.1007/S00109-015-1376-X |
| P698 | PubMed publication ID | 26689709 |
| P2093 | author name string | Yang Liu | |
| Xuetao Cao | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination | Q24652965 | ||
| Cancer immunoediting from immune surveillance to immune escape | Q24655415 | ||
| Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators | Q26782799 | ||
| Immune cell promotion of metastasis | Q26991724 | ||
| Innate and adaptive immune cells in the tumor microenvironment | Q27008342 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Lymphoma: immune evasion strategies | Q28080705 | ||
| Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected | Q28084627 | ||
| Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer | Q28241808 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| Adoptive immunotherapy for cancer: harnessing the T cell response | Q28262548 | ||
| Coordinated regulation of myeloid cells by tumours | Q28395157 | ||
| CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis | Q29614347 | ||
| Microenvironmental regulation of tumor progression and metastasis | Q29615504 | ||
| Macrophage diversity enhances tumor progression and metastasis | Q29615847 | ||
| Tumor metastasis: molecular insights and evolving paradigms | Q29615908 | ||
| Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN | Q29619346 | ||
| Natural innate and adaptive immunity to cancer | Q29620313 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. | Q33648178 | ||
| Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice | Q33721765 | ||
| Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. | Q33763653 | ||
| Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 | ||
| Tumor-associated macrophages and survival in classic Hodgkin's lymphoma | Q33962334 | ||
| VISTA Regulates the Development of Protective Antitumor Immunity | Q33978040 | ||
| The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors | Q34228171 | ||
| Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape | Q34241893 | ||
| HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells | Q34353413 | ||
| The cellular and molecular origin of tumor-associated macrophages | Q34378833 | ||
| Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer | Q34527281 | ||
| Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells | Q34625607 | ||
| Macrophage regulation of tumor responses to anticancer therapies | Q34649588 | ||
| Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. | Q34655472 | ||
| Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells | Q34987934 | ||
| CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages | Q34995099 | ||
| Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia | Q34997704 | ||
| High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer | Q35212653 | ||
| New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape | Q35300077 | ||
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 | ||
| Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation | Q35579455 | ||
| CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients | Q35588533 | ||
| IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis | Q35763387 | ||
| Intratumoral dendritic cells in the anti-tumor immune response | Q35833610 | ||
| Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 | ||
| Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils | Q36141195 | ||
| TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. | Q36237549 | ||
| LAG-3 in Cancer Immunotherapy | Q36416383 | ||
| Regulatory T cells, tumour immunity and immunotherapy | Q36430144 | ||
| Checkpoint blockade in cancer immunotherapy | Q36490768 | ||
| Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells | Q36493469 | ||
| TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer | Q36845835 | ||
| The metastasis-promoting roles of tumor-associated immune cells | Q36972016 | ||
| Fas signal promotes the immunosuppressive function of regulatory dendritic cells via the ERK/β-catenin pathway | Q37201195 | ||
| Targeting the tumor microenvironment: from understanding pathways to effective clinical trials | Q37274132 | ||
| The polarization of immune cells in the tumour environment by TGFbeta | Q37454364 | ||
| Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. | Q37494817 | ||
| Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo | Q37631248 | ||
| Apoptotic cell administration enhances pancreatic islet engraftment by induction of regulatory T cells and tolerogenic dendritic cells. | Q37729626 | ||
| The mechanisms of cancer immunoescape and development of overcoming strategies | Q37849666 | ||
| Combining immunotherapy and targeted therapies in cancer treatment | Q37995939 | ||
| Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells | Q38167887 | ||
| Tumor-associated macrophages: from mechanisms to therapy | Q38230880 | ||
| The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis | Q38235867 | ||
| Immune evasion in cancer: Mechanistic basis and therapeutic strategies. | Q38394302 | ||
| RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis | Q38844181 | ||
| Prostanoid induces premetastatic niche in regional lymph nodes | Q38951674 | ||
| Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. | Q38993068 | ||
| JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells | Q39020685 | ||
| Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. | Q39507131 | ||
| Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. | Q39722616 | ||
| Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells | Q39881074 | ||
| Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression | Q40626645 | ||
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
| Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab | Q41591884 | ||
| Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity | Q41877015 | ||
| Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated | Q42799339 | ||
| Cancer immunology. Identifying the infiltrators | Q44853108 | ||
| Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease | Q45162594 | ||
| The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells. | Q45950820 | ||
| An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy | Q46538900 | ||
| Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. | Q50449094 | ||
| CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies--Immuno-oncology Advances Clinical Cancer Research. | Q50852978 | ||
| Immunotherapy: PI3Kδ inhibition lifts the breaks on antitumour immunity. | Q54341097 | ||
| Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. | Q54597476 | ||
| Human hepatocellular carcinoma-infiltrating CD4⁺CD69⁺Foxp3⁻ regulatory T cell suppresses T cell response via membrane-bound TGF-β1 | Q56896907 | ||
| An innate regulatory cell | Q57265277 | ||
| Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse | Q58211903 | ||
| Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis | Q59052622 | ||
| Turning macrophages on, off and on again | Q60455923 | ||
| Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer | Q73311980 | ||
| The origin and function of tumor-associated macrophages | Q85309668 | ||
| Helper T cell diversity and plasticity | Q85932557 | ||
| P433 | issue | 5 | |
| P921 | main subject | evasion of host immune response | Q1660157 |
| P304 | page(s) | 509-522 | |
| P577 | publication date | 2015-12-22 | |
| P1433 | published in | Journal of Molecular Medicine | Q6295593 |
| P1476 | title | Immunosuppressive cells in tumor immune escape and metastasis | |
| P478 | volume | 94 |
| Q38653990 | A distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma. |
| Q89967040 | Advanced Cancer Imaging Applied in the Comparative Setting |
| Q104617809 | An insight into small extracellular vesicles: Their roles in colorectal cancer progression and potential clinical applications |
| Q49986605 | C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer |
| Q64992084 | CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance? |
| Q90419614 | Calcitriol and Its Analogs Establish the Immunosuppressive Microenvironment That Drives Metastasis in 4T1 Mouse Mammary Gland Cancer |
| Q49260236 | Cancer vaccine: learning lessons from immune checkpoint inhibitors |
| Q33709719 | Circulating tumor cells promote the metastatic colonization of disseminated carcinoma cells by inducing systemic inflammation |
| Q64108497 | Effects of exosomes on pre-metastatic niche formation in tumors |
| Q64251507 | European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment |
| Q92222186 | Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy |
| Q91643282 | From Tumor Metastasis towards Cerebral Ischemia-Extracellular Vesicles as a General Concept of Intercellular Communication Processes |
| Q47614650 | Gastric cancer tissue-derived mesenchymal stem cells impact peripheral blood mononuclear cells via disruption of Treg/Th17 balance to promote gastric cancer progression |
| Q90642725 | Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment |
| Q93049869 | IL-9 Exerts Antitumor Effects in Colon Cancer and Transforms the Tumor Microenvironment In Vivo |
| Q38810969 | In silico polypharmacology of natural products |
| Q91651633 | Increased Expression of Myeloid-Derived Suppressor Cells in Patients with HBV-Related Hepatocellular Carcinoma |
| Q50858477 | Integrative strategy for improving cancer immunotherapy. |
| Q92683978 | Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice |
| Q91973745 | LncRNA NEAT1 Interacted With DNMT1 to Regulate Malignant Phenotype of Cancer Cell and Cytotoxic T Cell Infiltration via Epigenetic Inhibition of p53, cGAS, and STING in Lung Cancer |
| Q64956003 | Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives. |
| Q93132566 | Nanosecond pulsed electric field inhibits malignant melanoma growth by inducing the change of systemic immunity |
| Q90706153 | PD-L1 expression levels on tumor cells affect their immunosuppressive activity |
| Q64236874 | Perspectives on immunotherapy via oncolytic viruses |
| Q64104277 | Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model |
| Q64119077 | Role of Microenvironment on the Fate of Disseminating Cancer Stem Cells |
| Q48047291 | Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6. |
| Q92327569 | Small Particles, Big Effects: The Interplay Between Exosomes and Dendritic Cells in Antitumor Immunity and Immunotherapy |
| Q90107158 | TCR-like antibodies in cancer immunotherapy |
| Q92158148 | Target Elimination-Denatured and Unstable Proteins, Environmental Toxins, Metabolic Wastes, Immunosuppressive Factors and Chronic Inflammatory Factors of Medical System for Chronic Diseases Prevention and Health Promotion: A Narrative Review |
| Q64996748 | The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas. |
| Q98771252 | The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study |
| Q26750877 | The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression |
| Q102141453 | The dynamic behavior of lipid droplets in the pre-metastatic niche |
| Q90589889 | The function and clinical application of extracellular vesicles in innate immune regulation |
| Q89821427 | Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease |
| Q92059895 | Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice |
Search more.